Enteritis: Clinical Trials

71 trials for Enteritis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 completed, 15 unknown, 9 terminated, 7 recruiting. 18 Phase 2, 16 Not applicable, 10 Phase 3, 9 Phase 1, 8 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 218Completed 8, Terminated 6, Recruiting 2, Suspended 1, Unknown 1
Not applicable16Completed 7, Unknown 6, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 310Completed 5, Terminated 3, Active not recruiting 1, Recruiting 1
Phase 19Completed 4, Terminated 2, Recruiting 1, Unknown 1, Withdrawn 1
Phase 48Recruiting 3, Completed 2, Not yet recruiting 2, Unknown 1
Early Phase 13Completed 1, Not yet recruiting 1, Recruiting 1

Follow Enteritis: new trials by email Literature Review of Enteritis trials Research Report on Enteritis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery
5-ASA, Placebo - Ulcerative Colitis (UC), Pouchitis
Phase 4Not yet recruitingUniversity Hospital, Linkoeping1102027-04-012026-08-19
Oral Aeromonas sp. MTB Phage Therapy for Pouchitis in Patients With Ulcerative Colitis (UC)
MTB-targeted phage therapy - Pouchitis, UC - Ulcerative Colitis
Early Phase 1Not yet recruitingJinling Hospital, China122027-01-012026-10-22
Emerging Indications for Hyperbaric Oxygen Treatment
Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis
Phase 4Not yet recruitingJay C. Buckey Jr.1002026-11-012026-09-09
Etrasimod as Prevention of Pouchitis
etrasimod, Placebo - Pouchitis
Phase 2RecruitingMaia Kayal402026-07-012026-09-21
CLF065 for Chronic Pouchitis
CLF065, Placebo - Pouchitis
Phase 2SuspendedCalibr, a division of Scripps Research202026-06-012026-07-09
GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis
Guselkumab, Diet - Pouchitis
Phase 4RecruitingUniversitaire Ziekenhuizen KU Leuven202026-04-232026-05-05
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC) - Pouchitis, Pouches, Ileoanal
Phase 4RecruitingUniversity of North Carolina, Chapel Hill252025-08-122026-01-30
Exploring the Influence of Trptophan on the Treatment of Pouchitis
Tryptophan 25mg/kg bodyweight, Placebo - Pouchitis
Not applicableNot yet recruitingUniversitätsklinikum Hamburg-Eppendorf202025-04-012025-03-06
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
Vedolizumab, Concomitant Antibiotic Therapy - Pouchitis
Phase 3RecruitingTakeda302024-11-192026-08-03
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
Fecal Microbiota Transplant (FMT) - Chronic Pouchitis, Pouchitis
Early Phase 1RecruitingMaia Kayal162024-10-032026-08-17
Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis
Intestinal Ultrasound - Ulcerative Colitis, Pouchitis
Not applicableCompletedMayo Clinic662024-07-012026-08-12
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Rifaximin 550 MG Oral Tablet [XIFAXAN] - Pouchitis
Phase 4RecruitingUniversity of North Carolina, Chapel Hill162024-07-012026-08-03
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)
EXE-346, Placebo - Ileal Pouch
Phase 1 / Phase 2RecruitingExegi Pharma, LLC502023-11-062026-05-28
Stem Cells for the Treatment of Pouchitis
Mesenchymal Stem Cells (MSCs) - Pouchitis, Crohn's Disease
Phase 1WithdrawnThe Cleveland Clinic2022-04-012026-04-16
Efficacy of Liraglutide Therapy in Patients With IPAA
Liraglutide Pen Injector, Placebo Pen Injector - Pouchitis, Irritable Pouch Syndrome
Phase 2TerminatedUniversity of North Carolina, Chapel Hill82022-03-222024-07-23
Assessment of Patients With Acute Pouchitis Treated With Antibiotics
Observational, No intervention - Pouchitis, Ulcerative Colitis
SuspendedAlimentiv Inc.432021-12-072024-02-20
GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery
GM-CSF, fosfomycin and metronidazole - Pouchitis
Phase 1 / Phase 2UnknownZealand University Hospital182021-09-062023-01-26
Oral Probiotics on Radiation Enteritis Stage Ⅱ Induced by Pelvic Concurrent Chemoradiotherapy
probiotics - Pelvic Cancer, Enteritis, Probiotics,Chemoradiotherapy
Not applicableUnknownJiangxi Provincial Cancer Hospital402021-08-272021-09-02
Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy
Eupatilin, Rebamipide - Rheumatoid Arthritis, Osteoarthritis
Phase 4UnknownSeoul National University Boramae Hospital502021-06-012021-05-13
Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis
Faecal microbiota transplantation - Pouchitis, Inflammatory Bowel Diseases
Not applicableCompletedOle Thorlacius-Ussing, MD, DMSc, Professor of Surgery32021-03-012022-07-13

Showing 20 of 71. Sign in to see all of them.

Narrower conditions

Pouchitis (50)  ·  Colitis, Ulcerative (23)  ·  Crohn Disease (10)  ·  Inflammatory Bowel Diseases (6)  ·  Diarrhea (4)  ·  Ileitis (4)  ·  Escherichia coli Infections (3)  ·  Abdominal Pain (2)  ·  Adenomatous Polyposis Coli (2)  ·  Anastomotic Leak (2)  ·  Colitis (2)  ·  Colorectal Neoplasms (2)  ·  Duodenitis (2)  ·  Gastritis (2)

Broader conditions

Digestive System Diseases (71)  ·  Gastroenteritis (71)  ·  Gastrointestinal Diseases (71)  ·  Intestinal Diseases (70)  ·  Ileal Diseases (53)  ·  Ileitis (49)  ·  Colonic Diseases (25)  ·  Colitis (22)  ·  Inflammatory Bowel Diseases (20)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Infections (7)  ·  Bacterial Infections (6)  ·  Bacterial Infections and Mycoses (6)  ·  Signs and Symptoms (6)

Interventions

Fecal Microbiota Transplantation (6)  ·  AST 120 (2)  ·  Diet (2)  ·  Hyperbaric Oxygenation (2)  ·  Probiotics (2)  ·  vedolizumab (2)  ·  Adalimumab (1)  ·  Ciprofloxacin (1)  ·  Clotrimazole (1)  ·  FODMAP Diet (1)  ·  Food, Formulated (1)  ·  Fosfomycin (1)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (1)  ·  Liraglutide (1)  ·  Medical Marijuana (1)

Sponsors

University of North Carolina, Chapel Hill (4)  ·  Tel-Aviv Sourasky Medical Center (3)  ·  Charite University, Berlin, Germany (2)  ·  Jinling Hospital, China (2)  ·  Johns Hopkins Bloomberg School of Public Health (2)  ·  Maia Kayal (2)  ·  Mayo Clinic (2)  ·  Ocera Therapeutics (2)  ·  Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery (2)  ·  Sahlgrenska University Hospital (2)  ·  Takeda (2)  ·  Universitaire Ziekenhuizen KU Leuven (2)  ·  Aalborg University Hospital (1)  ·  Alimentiv Inc. (1)  ·  Applied Molecular Transport (1)

Countries

United States (32)  ·  Belgium (7)  ·  Canada (7)  ·  Israel (6)  ·  Netherlands (6)  ·  Denmark (5)  ·  France (5)  ·  Germany (5)  ·  China (4)  ·  Italy (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Sweden (3)  ·  Australia (2)  ·  Finland (2)

Top investigators

Ole Thorlacius-Ussing, Professor (3)  ·  Edward Barnes, MD, MPH (2)  ·  Hans Herfarth, MD, PhD (2)  ·  A. Masclee, Prof MD PhD (1)  ·  Alastair Forbes, BSc MD FRCP ILTM (1)  ·  Amy L Lightner, MD (1)  ·  Antonio Di Sabatino, MD (1)  ·  Bo Shen, M.D. (1)  ·  Bo Shen, MD (1)  ·  Carl Brown (1)  ·  Chien-Chang Chen, MD (1)  ·  Chris Dunk (1)  ·  Chunling Jiang, MD,PHD (1)

Results publications

PMID 19415309, PMID 20135748, PMID 21549404, PMID 21601883, PMID 21983950, PMID 23872668, PMID 24200199, PMID 25110406, PMID 28778448, PMID 32493442, PMID 33501942, PMID 36171082, PMID 36988594, PMID 38668926, PMID 38708959, PMID 38750870, PMID 39025255, PMID 39485259, PMID 39536721, PMID 40856818, PMID 42232317, PMID 42728546

NIH funding

2015 (1), 2023 (1), 2025 (1), R03DK067275 (1), R03DK140415 (1), R43CA141968 (1)